Balapiravir

Balapiravir
Balapiravir_structure.png
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number	690270-29-2
PubChem	11691726
DrugBank
ChemSpider	9866453
KEGG	D09582

Balapiravir (R-1626, Ro4588161) is an experimental antiviral drug which acts as a polymerase inhibitor. There were efforts to develop it as a potential treatment for hepatitis C, and it was subsequently also studied in Dengue fever, but was not found to be useful. Lower doses failed to produce measurable reductions in viral load, while higher doses produced serious side effects such as lymphopenia which precluded further development of the drug.<ref>,

 A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients., 
 J Infect Dis, 
 2013,
 Vol. 207(Issue: 9),
 pp. 1442–50,
 DOI: 10.1093/infdis/jis470,
 PMID: 22807519,
 PMC: 3610419,</ref> Subsequent research found that excess cytokine production triggered by Dengue virus infection prevented the conversion of the balapiravir prodrug to its active form, thereby blocking the activity of the drug.<ref>, 
 Activation of Peripheral Blood Mononuclear Cells by Dengue Virus Infection Depotentiates Balapiravir, 
 J. Virol., 
 2014,
 Vol. 88(Issue: 3),
 pp. 1740–1747,
 DOI: 10.1128/JVI.02841-13,
 PMID: 24257621,
 PMC: 3911617,</ref>

References

• 
  Balapiravir